Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia [Phase 4]

View source ↗

Summary

This Phase 4 study is recruiting to evaluate the efficacy and safety of zanubrutinib in treatment-naive Chinese adults with Waldenström macroglobulinemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: BeiGene | Conditions: Waldenström's Macroglobulinemia | Phase 4 | Status: RECRUITING